Endocrinology, Vol 133, 2502-2507, Copyright © 1993 by Endocrine Society

ARTICLES

Etidronate inhibits the thyroid hormone-induced bone loss in rats assessed by bone mineral density and messenger ribonucleic acid markers of osteoblast and osteoclast function

B Ongphiphadhanakul, LG Jenis, LE Braverman, S Alex, GS Stein, JB Lian and DT Baran
Division of Endocrinology, University of Massachusetts Medical School, Worcester 01655.

TSH-suppressive doses of thyroid hormone are associated with bone loss. We have previously reported that L-T4 decreases femoral, but not vertebral bone mineral density (BMD) in rats. As bisphosphonates are able to decrease bone resorption, especially in high bone turnover states, we investigated the potential effects of etidronate disodium (EHDP) on L-T4-induced bone loss in the rat model by assessing BMD and gene expression of osteoblast (osteocalcin, osteopontin, type I collagen, and alkaline phosphatase), osteoclast (tartrate-resistant acid phosphatase), and cell growth (histone) markers in the skeleton. L- T4 administered for 20 days decreased BMD in the femur, but had no effect on the lumbar spine. EHDP alone had no effect on femoral or vertebral BMD, but did prevent the L-T4-induced bone loss in the femur. L-T4 increased mRNA levels of alkaline phosphatase, tartrate-resistant acid phosphatase, and histone H4 in the femur, but not in the vertebrae. EHDP, which alone had no effect on gene expression in the femur or vertebrae, inhibited the effect of L-T4 on mRNA markers in the femur. The results demonstrate that EHDP can prevent the L-T4-induced decrease in femoral BMD in rats that is associated with the prevention of changes in mRNA markers of osteoclast and osteoblast function. EHDP and other bisphosphonate compounds may be useful in the prevention of thyroid hormone-induced bone loss in humans.

This article has been cited by other articles:

				S. J. Hoffman, J. Vasko-Moser, W. H. Miller, M. W. Lark, M. Gowen, and G. Stroup Rapid Inhibition of Thyroxine-Induced Bone Resorption in the Rat by an Orally Active Vitronectin Receptor Antagonist J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 205 - 211. [Abstract] [Full Text] [PDF]

				J. Pfeilschifter and I. J. Diel Osteoporosis Due to Cancer Treatment: Pathogenesis and Management J. Clin. Oncol., April 7, 2000; 18(7): 1570 - 1593. [Abstract] [Full Text] [PDF]

				H. N. Rosen, A. C. Moses, J. Garber, D. S. Ross, S. L. Lee, L. Ferguson, V. Chen, K. Lee, and S. L. Greenspan Randomized Trial of Pamidronate in Patients with Thyroid Cancer: Bone Density Is Not Reduced by Suppressive Doses of Thyroxine, But Is Increased by Cyclic Intravenous Pamidronate J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2324 - 2330. [Abstract] [Full Text]

				M. Milne, M.-I. Kang, J. M. Quail, and D. T. Baran Thyroid Hormone Excess Increases Insulin-Like Growth Factor I Transcripts in Bone Marrow Cell Cultures: Divergent Effects on Vertebral and Femoral Cell Cultures Endocrinology, May 1, 1998; 139(5): 2527 - 2534. [Abstract] [Full Text] [PDF]

				B. Frenkel, C. Capparelli, M. van Auken, D. B. , J. Bryan, J. L. Stein, G. S. Stein, and J. B. Lian Activity of the Osteocalcin Promoter in Skeletal Sites of Transgenic Mice and during Osteoblast Differentiation in Bone Marrow-Derived Stromal Cell Cultures: Effects of Age and Sex Endocrinology, May 1, 1997; 138(5): 2109 - 2116. [Abstract] [Full Text] [PDF]